British drug dealer AstraZeneca (AZN.L) has begun testing an antibody-based cocktail for the prevention and treatment of COVID-19, adding to the latest signs of possible health solutions to the disease caused by the novel coronavirus.
The London-based company, which is already one of the leading players in the global competition to develop a successful vaccine, said the study would test whether AZD7442, a combination of two monoclonal antibodies (mAbs), was safe and tolerable for up to 48 healthy participants over a period of years. -18 and 55.
If the first UK stage trial, which made its participants available, proves that AZD7442 is safe, AstraZeneca said it will continue to test it as a prophylactic treatment for COVID-19 and for patients who have, in a dramatic way, in-time / late studies.
AstraZeneca shares had risen about 1% to 87 percent ($ 114) in initial trading.
The development of mAbs to detect the virus, a method already tested by Regeneron (REGN.O), ELi Lilly (LLY.N), Roche (ROG.S) and partners Molecular Partners (MOLN.S), has been approved by scientists leaders.
mAbs mimic natural antibodies produced in the body to fight infections and can be synthesized in a laboratory to treat disease in patients. Current use includes treatment for other types of cancer.
Infectious disease specialist in the U.S. Anthony Fauci called them a “guaranteed bet” against COVID-19, while AstraZeneca in June received $ 23.7 million sponsored by U.S. government companies.
“This combination of antibodies, combined with the expanded technology of our health, has the potential to improve performance and durability and reduce the chances of infection,” said Astra vice president of biopharmaceuticals R&D Mene Pangalos.
Although vaccines are at the heart of the long-term struggle against the epidemic, alternative therapies are being developed, and the United States on Sunday approved the use of plasma of COVID-19 patients to treat patients.
The Financial Times reported over the weekend that the administration of President Donald Trump was looking into the immediate approval of AstraZeneca’s COVID-19 vaccine ahead of the November election.